Preface to the English version
Preface to the Japanese Gastric Cancer Treatment Guidelines 5th edition
Treatments
Treatment modalities and their indications
Algorithm of standard treatments to be recommended in clinical practice
Summary of T, N, and M categories and stage grouping based on the 15th edition of the Japanese Classification of Gastric Carcinoma [1]
-
N1: the number of metastatic lymph nodes among the regional lymph nodes (No. 1–12. 14v) is 1–2, N2: 3–6, N3a: 7–15, N3b: ≥ 16.
-
M1: metastasis outside the regional lymph nodes (including CY1).
-
Stage grouping: See Table 1.Table 1Stage groupingM0M1N0N(+)any NClinical stages (cTNM, cStage, to be decided based on preoperative imaging, staging laparoscopy findings and intraoperative findings)T1 (M, SM)/T2 (MP)IIIAIVBT3 (SS)/T4a (SE)IIBIIIT4b(SI)IVAM0M1N0N1N2N3aN3bany NPathological stages (pTNM, pStage, to be decided based on pathologic findings of the resected specimen)T1a (M)/pT1b(SM)IAIBIIAIIBIIIBIVT2 (MP)IBIIAIIBIIIAIIIBT3 (SS)IIAIIBIIIAIIIBIIICT4a (S)IIBIIIAIIIAIIIBIIICT4b (SI)IIIAIIIBIIIBIIICIIIC
Surgery
Types and definitions of gastric surgery
Standard gastrectomy and non-standard gastrectomy in surgery with curative intent
Standard gastrectomy
Non-standard gastrectomy
Modified surgery
Extended surgery
Non-curative surgery
Palliative surgery
Reduction surgery
Extent of gastric resection
Surgery for gastric cancer
-
Total gastrectomy Total resection of the stomach including the cardia and pylorus.
-
Distal gastrectomy Stomach resection including the pylorus. The cardia is preserved. In the standard gastrectomy, two-third of the stomach is resected.
-
Pylorus-preserving gastrectomy (PPG) Stomach resection preserving the upper third of the stomach and the pylorus along with a portion of the antrum.
-
Proximal gastrectomy (PG) Stomach resection including the cardia (esophagogastric junction). The pylorus is preserved.
-
Segmental gastrectomy Circumferential resection of the stomach preserving the cardia and pylorus.
-
Local resection Non-circumferential resection of the stomach.
-
Non-resectional surgery (bypass surgery, gastrostomy, jejunostomy).
-
Completion gastrectomy Total resection of the remnant stomach including the cardia or pylorus depending on the type of previous gastrectomy.
-
Subtotal resection of remnant stomach Distal resection of the remnant stomach preserving the cardia.
Determination of the extent of gastric resection
Resection margin
Selection of gastrectomy
-
Pylorus-preserving gastrectomy (PPG): for tumors in the middle portion of the stomach with the distal tumor border at least 4 cm proximal to the pylorus.
-
Proximal gastrectomy: for proximal tumors where more than half of the distal stomach can be preserved.
-
Local resection of the stomach and segmental gastrectomy should still be regarded as investigational treatments.
Lymph node dissection
Extent of lymph node dissection
Definition of the D levels
Total gastrectomy (Fig. 2)
-
D0: Lymphadenectomy less than D1.
-
D1: No. 1–7.
-
D1+: D1 + No. 8a, 9, 11p.
-
D2: D1 + No. 8a, 9, 11p, 11d, 12a.
Distal gastrectomy (Fig. 3)
-
D0: Lymphadenectomy less than D1.
-
D1: No. 1, 3, 4sb, 4d, 5, 6, 7.
-
D1+: D1 + No. 8a, 9.
-
D2: D1 + No. 8a, 9, 11p, 12a.
Pylorus-preserving gastrectomy (Fig. 4)
-
D0: Lymphadenectomy less than D1.
-
D1: No. 1, 3, 4sb, 4d, 6, 7.
-
D1+: D1 + No. 8a, 9.
Proximal gastrectomy (Fig. 5)
-
D0: Lymphadenectomy less than D1.
-
D1: No. 1, 2, 3a, 4sa, 4sb, 7
-
D1+: D1 + No. 8a, 9, 11p.
Indications for lymph node dissection
D1 lymphadenectomy
D1+ lymphadenectomy
D2 lymphadenectomy
D2+ lymphadenectomy
-
Dissection of No. 10 (splenic hilar lymph nodes) with or without splenectomy for cancer of the upper stomach invading the greater curvature (D2 + No. 10). This procedure had been defined as D2 lymphadenectomy in the previous editions of the Japanese Gastric Cancer Treatment Guidelines (CQ4).
-
Dissection of No. 14v (superior mesenteric venous lymph node) for cancer of the distal stomach tumor with metastasis to the No. 6 lymph nodes (D2 + No. 14v).
-
Dissection of No. 13 (posterior pancreas head lymph node) for cancer invading the duodenum (D2 + No. 13) [6]. Metastases to the No. 13 nodes, which are not included in the regional lymph nodes for gastric cancer, should usually be classified as M1. However, since the No. 13 nodes are among the regional lymph nodes for cancer of the duodenum according to the TNM classification and the Japanese Classification of Gastric Carcinoma 15th edition, these should be regarded as regional lymph nodes once gastric cancer invades the duodenum.
-
Dissection of No. 16 (abdominal aortic lymph node) after neoadjuvant chemotherapy for cancer with an extensive lymph node involvement (D2 + No. 16) (CQ5).
Junctional cancer (diameter less than 4 cm)
Extent of the resection of the esophagus and stomach
Extent of lymphadenectomy
Miscellaneous
Vagal nerve preservation
Omentectomy
Bursectomy
Combined resection of adjacent organ(s)
Approaches to the lower esophagus
Laparoscopic surgery
Reconstruction after gastrectomy
Total gastrectomy
-
Roux-en-Y esophagojejunostomy.
-
Jejunal interposition.
-
Double tract method.
Distal gastrectomy
-
Billroth I gastroduodenostomy.
-
Billroth II gastrojejunostomy.
-
Roux-en-Y gastrojejunostomy.
-
Jejunal interposition.
Pylorus-preserving gastrectomy
-
Gastro-gastrostomy.
Proximal gastrectomy
-
Esophagogastrostomy.
-
Jejunal interposition.
-
Double tract method.
Endoscopic resection
Methods of endoscopic resection (CQ11)
Endoscopic mucosal resection (EMR)
Handling of endoscopically resected specimens
Handling of resected specimens
Definition of differentiated-type and undifferentiated-type carcinoma
Histological predominance and intratumoral ulcerative findings (UL)
Indication for endoscopic resection
Principles of indication
Indication
-
A differentiated-type adenocarcinoma without ulcerative findings (UL0), in which the depth of invasion is clinically diagnosed as T1a and the diameter is > 2 cm.
-
A differentiated-type adenocarcinoma with ulcerative findings (UL1), in which the depth of invasion is clinically diagnosed as T1a and the diameter is ≤ 3 cm.
-
An undifferentiated-type adenocarcinoma without ulcerative findings (UL0) in which the depth of invasion is clinically diagnosed as T1a and the diameter is ≤ 2 cm. Lesions in this category are currently excluded from the absolute indication due to the lack of sufficient evidence for long-term outcome, but may in future be included pending results of the JCOG1009/1010 study.
Curability of endoscopic resection
Evaluation of curability
Endoscopic curability A (eCuraA)
Endoscopic curability B (eCuraB)
Endoscopic curability C (eCuraC)
Treatments after endoscopic resection (Fig. 7)
Treatments after eCuraA or eCuraB
Treatments after eCuraC-1
Treatments after eCuraC-2
Total points | Number of patients (n = 1101) | Number of patients with lymph node metastasis (n = 94) | Incidence of nodal metastasis (%) |
---|---|---|---|
0 | 62 | 1 | 1.6 |
1 | 341 | 9 | 2.6 |
2 | 185 | 9 | 4.9 |
3 | 148 | 11 | 7.4 |
4 | 132 | 11 | 8.3 |
5 | 141 | 28 | 19.9 |
6 | 77 | 21 | 27.3 |
7 | 15 | 4 | 26.7 |
Systemic chemotherapy for unresectable advanced/recurrent gastric cancer (AGC) (CQ13–CQ22)
Principles of indication of systemic chemotherapy for AGC
Standard criteria for a patient to be indicated for systemic chemotherapy
-
Histologically proven gastric cancer
-
PS 0–2. Chemotherapy is generally not recommended for patients with PS 3 or worse, and the decision to make an exception to the rule should be made discreetly considering the safety and clinical consequences for each individual (safety is of a particular concern for AGC with massive ascites or extensive peritoneal metastases).
-
Preserved major organ function
-
No serious comorbidities
-
Written informed consent obtained from the patient
Routine evaluations before and during chemotherapy
Anti-cancer agents
Definition of the recommendation grade and evidence level endowed to each chemotherapeutic regimen
“Recommended regimens”
-
Significant superiority over, or non-inferiority to, the conventional standard treatment in terms of overall survival has been proven by a domestic or international phase III clinical trial.
-
Reproducible clinical benefit has been demonstrated by multiple domestic or international phase II clinical trials for a specific patient group.
-
The regimen has served as a control arm in multiple domestic or international phase III clinical trials, and has been considered as one of the standard regimens.
“Conditionally recommended regimens”
-
The regimen is considered as having clinical benefit under a specific condition in which the patient may not tolerate the “Recommended regimen”.
-
The regimen is considered as having shown clinical benefit based on the wide usage in Japan as general practice or through interpretation of relevant clinical trials, even though the evidence is not robust enough for inclusion into the “Recommended regimen”.
A (strong) | Strong reliability in the expected value of the effect |
B (moderate) | Moderate reliability in the expected value of the effect |
C (modest): | Limited reliability in the expected value of the effect |
D (weak) | Almost not reliable for the expected value of the effect |
First-line treatment for unresectable advanced/recurrent gastric cancer
HER2-negative gastric cancer
HER2-positive gastric cancer
Second-line treatment for unresectable advanced/recurrent gastric cancer
Adjuvant chemotherapy (CQ23–26)
Clinical significance of postoperative adjuvant chemotherapy
Indications
Palliative care
Clinical pathway after surgery for gastric cancer
Clinical items | Date on the clinical pathway |
---|---|
Removal of nasogastric tube | Before or on postoperative day 1 |
Initiation of oral fluid intake | On or after postoperative day 1 |
Initiation of solid food intake | Between postoperative days 2–4 |
Prophylactic administration of antibiotics | Only on the day of operation |
Removal of epidural tube | Before or on postoperative day 3 |
Removal of urinary catheter | Before or on postoperative day 3 |
Intravenous fluid administration | Until postoperative days 5–7 |
Removal of intra-abdominal drains | Before or on postoperative day 5 |
Discharge from the hospital | Between postoperative days 8–14 |